You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
嘉和生物(6998.HK)首日上市高開21.67% 高瓴淡馬錫為基石投資者
格隆匯 10-07 09:21
格隆匯10月7日丨嘉和生物(6998.HK)首日上市高開21.67%報29.2港元,盤前成交9.17億港元,最新總市值140億港元。公司是一家生物製藥巨頭,致力於開發和商業化腫瘤學和自身免疫性藥物。已成功研發出靶向通路極具潛力的候選藥物,涵蓋全球前三大腫瘤靶點及前十款暢銷藥物中的五款。公司稱預計未來12~18個月內將持續向中國藥監局和FDA提交NDA及多項臨牀研究新藥申請。公司此次IPO價格為24港元,公開發售獲1247倍認購,成為今年超購倍數第五高的新股。公司獲全球頂尖機構投資者和老牌藥企入股,包括高瓴資本旗下HHJH及HM Healthcare,康恩貝旗下子公司康嘉醫療及康和醫療,淡馬錫旗下的Aranda Investments等。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account